Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Maintaining work-life balance. Eating a healthy diet.
Balance is something our minds and bodies are constantly striving for.
For example, when the lungs are damaged by cigarette smoke or infections, the body sets to work, trying to repair the damage. Underlying this process is a type of cell known as the myofibroblast, which are recruited to the site of injury to orchestrate wound-healing responses, including scar formation.
The problem is, just as we sometimes fail at balancing our lifestyles, the body can get it wrong. In the case of repeated injury to the lung, myofibroblasts can become over-active; this promotes the formation of excessive scar tissue – so much so that the organ becomes inflexible, resulting in a serious condition known as pulmonary fibrosis.
As fibrosis worsens, individuals with pulmonary fibrosis find it harder and harder to breathe and the transport of oxygen into the bloodstream becomes insufficient – causing respiratory failure and death.
It is not exactly known how myofibroblasts are activated to promote organ scarring. To address this issue, a team led by Krembil Senior Scientist Dr.
Mohit Kapoor, including co-lead investigators Dr. David Lagares and the late Dr. Andrew Tager (both from Harvard University), initiated a study to explore the molecular signals that activate myofibroblasts in people with pulmonary fibrosis.
In the study, the researchers compared lung myofibroblasts isolated from people with or without pulmonary fibrosis, and found that the level of Ephrin-B2, a protein on the surface of cells, was higher in myofibroblasts from fibrotic lungs.
Using a series of experimental models, they discovered that an enzyme called ADAM10 causes part of Ephrin-B2 to be cleaved from the surface of the cell. The released piece, called sEphrin-B2, instructs myofibroblasts to migrate to the site of injury, generate scar tissue and promote fibrosis.
The team also found that administering sEphrin-B2 protein under the skin caused skin fibrosis, further implicating this molecule as a key player in the formation of excessive scar tissue. Further, by blocking the activity of ADAM10, they found that less sEphrin-B2 was released, resulting in reduced activation of myofibroblast cells and reduced fibrosis.
"Our study provides the first proof of concept that the ADAM10-sEphrin-B2 pathway drives organ fibrosis," explains Dr. Lagares.
Dr. Kapoor adds: "These results provide new targets for the development of therapies to prevent organ failure by preventing fibrosis – not only in the lungs and skin, but also in other tissues affected by fibrosis such as joints, the heart, the liver and the kidney."
This work was supported by Université de Montréal, the American Thoracic Society Foundation, the Pulmonary Fibrosis Foundation, the Scleroderma Foundation, the National Institutes of Health, the Scleroderma Research Foundation and the Toronto General & Western Hospital Foundation.